Medical devices developer Biocorp has entered into an agreement with science and technology firm Merck to develop a specific version of Mallya, a Bluetooth enabled clip-on device.
Under the deal, the companies will develop and supply the specific version of Mallya device for the monitoring of treatment adherence in the field of human growth hormone (HGH).
The device, which is produced in France’s Clermont-Ferrand, is used for pen injectors that collects dose and time of each injection and transfers information in real time to a companion software.
Mallya is claimed to be the first in its category to secure the CE-mark and commercial versions for insulin pen injectors are already available and distributed in Europe and other geographies.
The device will allow patients, including children and teenagers, to automatically keep track of their HGH daily injection and monitor adherence with their treatment plan.
Upon the completion of different milestones, Merck will pay up to €3m to develop the specific solution.
Biocorp will manufacture the commercial units on behalf of Merck, after the development phase. It will help generate additional revenues.
The objective is to sell the product on a global scale, once the development is completed.
Biocorp CEO Éric Dessertenne said: “We are very excited about this new agreement concerning Mallya. Not only are we collaborating with a new major player in the pharmaceutical industry, but we are also expanding the scope of Mallya.
“After the monitoring of patients living with diabetes, our medical device proves its usefulness and safety for children and teenagers undergoing growth hormone injection.”
Biocorp is engaged in the designing, development and manufacturing of medical devices and delivery systems.
